Clinical Journal of the American Society of Nephrology

Journal

Publication Venue For

  • Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial. 2020
  • Stepping into the Void: Remunerating, Valuing, and Understanding Nephrologists. 2020
  • End points for clinical trials in primary hyperoxaluria.  15:1056-1065. 2020
  • AKI!Now Initiative: Recommendations for Awareness, Recognition, and Management of AKI. 2020
  • Fibroblast Growth Factor 23 and the Last Mile. 2020
  • Ambulatory blood pressure phenotypes in adults taking antihypertensive medication With and Without CKD.  15:501-510. 2020
  • Pregnancy in a kidney transplant patient.  15:120-122. 2020
  • Prevention of bloodstream infections in patients undergoing hemodialysis.  15:132-151. 2020
  • Apol1 nephropathy risk alleles and risk of sepsis in blacks.  14:1733-1740. 2019
  • Self-reported incident hypertension and long-term kidney function in living kidney donors compared with healthy nondonors.  14:1493-1499. 2019
  • Early glomerular hyperfiltration and long-term kidney outcomes in type 1 diabetes: The DCCT/EDIC experience.  14:854-861. 2019
  • Growth pattern of kidney cyst number and volume in autosomal dominant polycystic kidney disease.  14:823-833. 2019
  • Quality improvement goals for acute kidney injury.  14:941-953. 2019
  • Vascular access for hemodialysis patients: New data should guide decision making.  14:954-961. 2019
  • Post-transplant lymphoproliferative disorder in a kidney transplant recipient.  14:751-753. 2019
  • Kidney transplantation in a HIV-positive recipient.  14:614-616. 2019
  • Management of the hemodialysis patient with catheter-related bloodstream infection.  14:611-613. 2019
  • Incidence and risk factors of early onset neonatal AKI.  14:184-195. 2019
  • PTH, FGF23, and intensive blood pressure lowering in chronic kidney disease participants in SPRINT.  13:1816-1824. 2018
  • Association of preexisting arterial intimal hyperplasia with arteriovenous fistula outcomes.  13:1358-1363. 2018
  • Postoperative ultrasound, unassisted maturation, and subsequent primary patency of arteriovenous fistulas.  13:1364-1372. 2018
  • Expand the pool of living donors for kidney transplantation.  13:1142-1143. 2018
  • Overcoming translational barriers in acute kidney injury: A report from an NIDDK workshop.  13:1113-1123. 2018
  • Clinical trial end points for hemodialysis vascular access: Background, rationale, and definitions.  13:490-494. 2018
  • Definitions and end points for interventional studies for arteriovenous dialysis access.  13:501-512. 2018
  • Recommended clinical trial end points for dialysis catheters.  13:495-500. 2018
  • Challenges in developing new therapies for vascular access dysfunction.  12:2053-2055. 2017
  • Perspectives from the kidney health initiative on advancing technologies to facilitate remote monitoring of patient self-care in RRT.  12:1900-1909. 2017
  • Vascular access type and clinical outcomes among elderly patients on hemodialysis.  12:1823-1830. 2017
  • Managing issues in dialysis for the patient with AKI.  12:1538-1542. 2017
  • Access to kidney transplantation among HIV-infected waitlist candidates.  12:467-475. 2017
  • Diagnosis, treatment, and prevention of hemodialysis emergencies.  12:357-369. 2017
  • Reassessing recommendations for choice of vascular access.  12:865-867. 2017
  • Survival benefit of transplantation with a deceased diabetic donor kidney compared with remaining on the waitlist.  12:974-982. 2017
  • The use of a multidimensional measure of dialysis adequacy—moving beyond small solute kinetics.  12:839-847. 2017
  • Predictors of initiation for predialysis arteriovenous fistula.  11:1802-1808. 2016
  • Automated segmentation of kidneys from mr images in patients with autosomal dominant polycystic kidney disease.  11:576-584. 2016
  • Genetic african ancestry and markers of mineral metabolism in CKD.  11:653-662. 2016
  • Association of dialysis duration with outcomes after transplantation in a Japanese cohort.  11:497-504. 2016
  • Visit-to-visit variability of BP and CKD outcomes: Results from the ALLHAT.  11:471-480. 2016
  • Acute kidney injury urine biomarkers in very low-birth-weight infants.  11:1527-1535. 2016
  • Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: The DCCT/EDIC study.  11:1969-1977. 2016
  • Association of peritonitis with hemodialysis catheter dependence after modality switch.  11:1999-2004. 2016
  • Association of reduced eGFR and albuminuria with serious fall injuries among older adults.  11:1236-1243. 2016
  • New insights into dialysis vascular access: Impact of preexisting arterial and venous pathology on AVF and AVG outcomes.  11:1495-1503. 2016
  • New insights into dialysis vascular access: Introduction.  11:1484-1486. 2016
  • New insights into dialysis vascular access: Molecular targets in arteriovenous fistula and arteriovenous graft failure and their potential to improve vascular access outcomes.  11:1504-1512. 2016
  • Paraprotein-related kidney disease: Kidney injury from paraproteins—What determines the site of injury?.  11:2288-2294. 2016
  • Pharmacokinetics and pharmacodynamics of extended infusion versus short infusion piperacillin-tazobactam in critically Ill patients undergoing CRRT.  11:1377-1383. 2016
  • Preoperative vascular medial fibrosis and arteriovenous fistula development.  11:1615-1623. 2016
  • A patient with recurrent arteriovenous graft thrombosis.  10:2255-2262. 2015
  • Serum uric acid and risk of CKD in type 2 diabetes.  10:1921-1929. 2015
  • The ethics of chronic dialysis for the older patient: Time to reevaluate the norms.  10:2094-2099. 2015
  • A prospective international multicenter study of AKI in the intensive care unit.  10:1324-1331. 2015
  • Identification of strategies to facilitate organ donation among african americans using the nominal group technique.  10:286-293. 2015
  • Progression of pediatric CKD of nonglomerular origin in the CKiD cohort.  10:571-577. 2015
  • The effects of cinacalcet in older and younger patients on hemodialysis: The evaluation of cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trial.  10:791-799. 2015
  • Renal relevant radiology: Use of ultrasonography in patients with AKI.  9:382-394. 2014
  • Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study.  9:64-71. 2014
  • A patient with AKI after cardiac surgery.  9:1470-1478. 2014
  • Nondisease-specific problems and all-cause mortality among older adults with CKD: The REGARDS study.  9:1737-1745. 2014
  • The demented patient who declines to be dialyzed and the unhappy armed police officer son: What should be done?.  9:804-808. 2014
  • Metabolic subtypes and risk of mortality in normal weight, overweight, and obese individuals with CKD.  8:2064-2071. 2013
  • Novel paradigms for dialysis vascular access: Downstream vascular biology-is there a final common pathway?.  8:2194-2201. 2013
  • Novel paradigms for dialysis vascular access: Introduction.  8:2183-2185. 2013
  • Preoperative venous intimal hyperplasia, postoperative arteriovenous fistula stenosis, and clinical fistula outcomes.  8:1750-1755. 2013
  • Prevalence of apparent treatment-resistant hypertension among individuals with CKD.  8:1583-1590. 2013
  • Future of medicare immunosuppressive drug coverage for kidney transplant recipients in the United States.  8:1258-1266. 2013
  • Segmentation of individual renal cysts from mr images in patients with autosomal dominant polycystic kidney disease.  8:1089-1097. 2013
  • Age at graft loss after pediatric kidney transplantation: Exploring the high-risk age window.  8:1019-1026. 2013
  • Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.  8:1009-1018. 2013
  • Long-term outcomes of arteriovenous thigh grafts in hemodialysis patients: A comparison with tunneled dialysis catheters.  8:804-809. 2013
  • AKI associated with synthetic cannabinoids: A case series.  8:523-526. 2013
  • Parietal epithelial cell activation marker in early recurrence of FSGS in the transplant.  7:1852-1858. 2012
  • Comparative effects of low-carbohydrate high-protein versus low-fat diets on the kidney.  7:1103-1111. 2012
  • Long-Term renal and cardiovascular outcomes in antihypertensive and Lipid-Lowering treatment to prevent heart attack trial (ALLHAT) participants by baseline estimated GFR.  7:989-1002. 2012
  • Design of clinical trials in AKI: A report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settings.  7:856-860. 2012
  • Design of clinical trials in acute kidney injury: A report from an NIDDK workshop-prevention trials.  7:851-855. 2012
  • Design of clinical trials in acute kidney injury: Report from an NIDDK workshop on trial methodology.  7:844-850. 2012
  • Use of secondary prevention medications among adults with reduced kidney function.  7:604-611. 2012
  • Academic interventional nephrology: A model for training, research, and patient care.  7:521-524. 2012
  • Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.  7:479-486. 2012
  • Pharmacokinetics and Pharmacodynamics of Piperacillin-Tazobactam in 42 patients treated with Concomitant CRRT.  7:452-457. 2012
  • (1-34) parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers.  7:139-145. 2012
  • Racial differences in the incidence of chronic kidney disease.  7:101-107. 2012
  • Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications.  6:2822-2828. 2011
  • Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study.  6:2871-2878. 2011
  • Late graft loss among pediatric recipients of DCD kidneys.  6:2705-2711. 2011
  • Age-specific association of reduced estimated glomerular filtration rate and albuminuria with all-cause mortality.  6:2200-2207. 2011
  • The spectrum of infections in catheter-dependent hemodialysis patients.  6:2247-2252. 2011
  • Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy.  6:1903-1911. 2011
  • Arteriovenous graft infection: A comparison of thigh and upper extremity grafts.  6:1739-1743. 2011
  • Barriers to evaluation and wait listing for kidney transplantation.  6:1760-1767. 2011
  • Introduction to the well-transplant visit-more than vital signs and a creatinine check.  6:1773. 2011
  • Decreased cumulative access survival in arteriovenous fistulas requiring interventions to promote maturation.  6:575-581. 2011
  • Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.  6:640-647. 2011
  • Dialysis fistula or graft: The role for randomized clinical trials.  5:2348-2354. 2010
  • Prognostic indicators of renal disease progression in adults with fabry disease: Natural history data from the Fabry Registry.  5:2220-2228. 2010
  • Galactose-deficient IgA1 in African Americans with IgA nephropathy: Serum levels and heritability.  5:2069-2074. 2010
  • Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: Updating the "trade-off" hypothesis.  5:1710-1716. 2010
  • Introduction to the Third Annual Rostand Vitamin D Symposium.  5:1696. 2010
  • Vitamin D, blood pressure, and African Americans: Toward a unifying hypothesis.  5:1697-1703. 2010
  • Does the heparin lock concentration affect hemodialysis catheter patency?.  5:1458-1462. 2010
  • Statin therapy is not associated with improved vascular access outcomes.  5:1447-1450. 2010
  • Optimizing medication adherence: An ongoing opportunity to improve outcomes after kidney transplantation.  5:1305-1311. 2010
  • Development, implementation, and results of the ASN in-training examination for fellows.  5:328-334. 2010
  • Enzyme replacement therapy and fabry nephropathy.  5:371-378. 2010
  • Introduction to focus on Fabry nephropathy: Biomarkers, progression, and disease severity.  5:359. 2010
  • Chronic calcineurin inhibitor nephrotoxicity: Reflections on an evolving paradigm.  4:2029-2034. 2009
  • Clinical outcomes of dialysis catheter-related candidemia in hemodialysis patients.  4:1102-1105. 2009
  • Does heparin coating improve patency or reduce infection of tunneled dialysis catheters?.  4:1787-1790. 2009
  • Mineralocorticoid receptor blockers and chronic kidney disease.  4:1685-1691. 2009
  • Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis.  4:560-566. 2009
  • A Festschrift honoring Dr. John J. Curtis..  4:2027-2028. 2009
  • Must health literacy be a prerequisite for kidney transplantation?.  4:16-17. 2009
  • Outcomes of brachiocephalic fistulas, transposed brachiobasilic fistulas, and upper arm grafts.  4:86-92. 2009
  • Introduction to vitamin D symposium, March 14, 2008.  3:1534. 2008
  • Evaluation and initial management of acute kidney injury.  3:962-967. 2008
  • Delivery of renal replacement therapy in acute kidney injury: What are the key issues?.  3:869-875. 2008
  • Development of a clinical research agenda for acute kidney injury using an international, interdisciplinary, three-step modified delphi process.  3:887-894. 2008
  • Disparities in fistula maturation persist despite preoperative vascular mapping.  3:437-441. 2008
  • Kidney transplantation as primary therapy for end-stage renal disease: A National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI™) conference.  3:471-480. 2008
  • Association between serum β2-microglobulin level and infectious mortality in hemodialysis patients.  3:69-77. 2008
  • Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) study.  2:1131-1139. 2007
  • Reliability of urinary albumin, total protein, and creatinine assays after prolonged storage: The family investigation of nephropathy and diabetes.  2:1156-1162. 2007
  • Role of β3 integrin in acute renal allograft rejection in humans.  2:1268-1273. 2007
  • Current management of vascular access.  2:786-800. 2007
  • Septic acute kidney injury in critically ill patients: Clinical characteristics and outcomes.  2:431-439. 2007
  • A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance..  1:79-87. 2006
  • Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group..  1:467-474. 2006
  • Survival advantage of black patients with kidney disease after acute myocardial infarction..  1:993-999. 2006
  • International Standard Serial Number (issn)

  • 1555-9041
  • Electronic International Standard Serial Number (eissn)

  • 1555-905X